Safety of oral resin for treatment of hyperkalemia in Chinese patients with renal insufficiency - SCRUTINIZE

Study identifier:D9483R00002

ClinicalTrials.gov identifier:NCT05462119

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A multicenter, prospective, non-interventional cohort study to evaluate the safety of oral resin for treatment of hyperkalemia in Chinese patients with renal insufficiency

Medical condition

Hyperkalaemia

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1000

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 22 Aug 2022
Estimated Primary Completion Date: 29 Dec 2023
Estimated Study Completion Date: 29 Dec 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria